
    
      This is the open-label extension to the randomized, double-blind, placebo-controlled SP650
      trial that assessed the efficacy and safety and tolerability of the Rotigotine patch in
      subjects with advanced-stage idiopathic Parkinson's Disease who are not well-controlled on
      Levodopa.
    
  